Voyager Therapeutics, Inc.
MX ˙ BMV ˙ US92915B1061
SecurityMX:VYGR / Voyager Therapeutics, Inc.
InstitutionCaptrust Financial Advisors
Latest Disclosed Ownership104,854 shares
Latest Disclosed Value $ 404,737
Captrust Financial Advisors reports 1.16% increase in ownership of VYGR / Voyager Therapeutics, Inc.

On May 14, 2026 - Captrust Financial Advisors filed a 13F-HR form disclosing ownership of 104,854 shares of Voyager Therapeutics, Inc. (MX:VYGR) valued at $404,737 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 17, 2026 disclosing 103,649 shares of Voyager Therapeutics, Inc.. This represents a change in shares of 1.16% during the quarter.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-14 2026-03-31 13F VOYAGER THERAPEUTICS INC COM Stock 92915B106 104,854 1,205 1.16 405 -0.74 0.0007
2026-02-17 2025-12-31 13F VOYAGER THERAPEUTICS INC COM Stock 92915B106 103,649 82 0.08 407 -15.73 0.0008
2025-11-19 2025-09-30 13F VOYAGER THERAPEUTICS INC COM Stock 92915B106 103,567 -400 -0.38 484 49.54 0.0010
2025-08-15 2025-06-30 13F VOYAGER THERAPEUTICS INC COM Stock 92915B106 103,967 -1,723 -1.63 323 -9.52 0.0007
2025-05-15 2025-03-31 13F VOYAGER THERAPEUTICS INC COM Stock 92915B106 105,690 -23,069 -17.92 357 -51.10 0.0009
2025-02-14 2024-12-31 13F VOYAGER THERAPEUTICS INC COM Stock 92915B106 128,759 313 0.24 730 -2.80 0.0021
2024-11-14 2024-09-30 13F VOYAGER THERAPEUTICS INC COM Stock 92915B106 128,446 -495 -0.38 751 -26.30 0.0022
2024-08-15 2024-06-30 13F VOYAGER THERAPEUTICS INC COM Stock 92915B106 128,941 -62 -0.05 1,020 -15.15 0.0033
2024-05-15 2024-03-31 13F VOYAGER THERAPEUTICS INC COM Stock 92915B106 129,003 103,852 412.91 1,201 466.51 0.0044
2024-02-14 2023-12-31 13F VOYAGER THERAPEUTICS INC COM Stock 92915B106 25,151 3,151 14.32 212 24.71 0.0007
2023-11-15 2023-09-30 13F VOYAGER THERAPEUTICS INC COM Stock 92915B106 22,000 0 0.00 170 -32.27 0.0007
2023-08-15 2023-06-30 13F VOYAGER THERAPEUTICS INC COM Stock 92915B106 22,000 22,000 252 0.0010
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.